Please note: AABB reserves the right to make updates to this program.
Wednesday, March 25, 2026
2:00 – 3:30 PM Eastern Time
Program Number: 26EL-616
Director/Moderator: Vasiliki E. Kalodimou, CABP(H), MSc, PhD, IARMES, Director at Flow Cytometry - Research & Regenerative Medicine Department, IASO Maternity & Research Hospital, Athens Greece; Assistant Professor, School of Medicine at the European University-Cyprus Ltd. Frankfurt Branch, and Former Acting Chair, School of Medicine at the European University-Cyprus Ltd. Frankfurt Branch; Associate Lecturer - Visiting - Health & Care Management at the Arden University Ltd ("The University"), UK; Board/Committee on Research Ethics at the National Hellenic Research Foundation (Ε.Ι.Ε), IASO, EUC-FRA, ARDEN-UK & E.I.E, Greece/Germany
Speakers:
We all face challenges in our daily work activities within biotherapies; artificial intelligence (AI) offers significant benefits like increased efficiency, improved decision-making, and automation, but also poses risks such as bias, job displacement, and ethical concerns. AI is being implemented across various sectors, including healthcare, leading to personalized services, enhanced diagnoses, and automated processes. AI advancements have revolutionized bioinformatics, enabling efficient data analysis, prediction of disease risk, and development of personalized treatments. AI can be leveraged to analyze vast datasets, identify patterns, and make predictions and improved healthcare outcomes.
However, potential downsides include the need for careful regulation, addressing algorithmic bias, and ensuring transparency and accountability.
What is the best approach to use AI?
After participating in this educational activity, participants should be able to:
Registration includes access to both the live and on-demand version of this eCast.
If you are a facility interested in participating in this eCast, simply complete the Group Viewing registration form and AABB will provide detailed instructions to share with your team approximately one week prior to the live program (each team member to register for the program utilizing a promocode). For single viewers, simply click on the Register button below to register.
Please note: registration for the live eCast will close 1 hour prior to the eCast start time. If you register after this time, you will receive access to the on-demand eCast when it is available.
| Single Viewer | Register |
| Group Viewing | Register |
This activity is eligible for one and a half (1.5) continuing education credit/contact hour for Physicians, Nurses, California Lab Personnel, Florida Lab Personnel and General Participation credit. AABB reserves the right to reduce or increase the number of credits granted based on the final activity duration. For more information on each credit type please visit our Continuing Education Credits webpage.
There is no financial support for this activity.
In support of improving patient care, this activity has been planned and implemented by the Association for the Advancement of Blood & Biotherapies (AABB), which is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians (ACCME): AABB designates this live activity for a maximum of one and a half (1.5) AMA PRA Category 1 CreditTM. AABB designates this enduring activity for a maximum of one and a half (1.5) AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Claiming Credit
Live Activity - Upon completion of the live activity, you will receive instructions to complete your evaluation, which is necessary to claim credit and receive your certificate of attendance/completion (credit must be claimed by the date provided in the instructions). The evaluation can be found by logging into the AABB Education Platform.
Enduring Activity - Once the enduring (on-demand) program is available, you will receive instructions to access the AABB Education Platform. Upon completion of viewing the enduring activity, you will need to complete the evaluation, which is necessary to claim credit and receive your certificate of completion (credit must be claimed by the date provided in the AABB Education Platform).
Program & Credit Expiration Dates:
Disclosure Declaration
It is the policy of the Association for the Advancement of Blood & Biotherapies to ensure independence, balance, objectivity, and scientific rigor and integrity in all of its CE activities. Faculty must disclose to the participants any relationships with commercial companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. AABB has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that the presence of such relationships will have a negative impact on the presentations.
Disclosures for the planners of this event can be found here. Disclosures for the program faculty, peer reviewers, and AABB personnel are provided at the beginning of the program.
Dr. Wanxing Cui is the Director of the Cell Therapy Manufacturing Facility at MedStar Georgetown University Hospital, where he oversees an FDA-registered operation adhering to standards set by the AABB, CAP, and FACT. With over 27 years of experience in pancreatic islet transplantation, he has significantly contributed to the Pancreatic Islets and Stem Cell Transplant and Cellular Immunotherapy programs at the hospital. Dr. Cui earned his Ph.D. in Molecular Medicine from Kyoto University, Japan, focusing on developing a bioartificial pancreas. He has authored over 70 peer-reviewed publications and holds several biotechnological patents. An active AABB assessor and FACT inspector, he contributes to advancing cell therapy standards. Additionally, he participates in the ISCT's iPSC Joint and Lab Practice Committees and serves as a mentor in ISCT's Professional Education Program (PEP) and AABB's Early Stage Professionals (ESP) programs. Dr. Cui is also a member of the AABB Cellular Therapies Section Coordinating Committee (CTSCC), furthering advancements in cell therapy.
Since 2006, Dr. Vasiliki Kalodimou has studied and working with stem cells from placenta, umbilical cord and adipose tissue, in every day practice and their applications in regenerative medicine, clinical trials, medical tourism and Flow Cytometry. Also is working in the area of human genetics & population genetics, soluble vitamins and stem cells and their role in human health as well as cellular standards.
In addition to collaboration with state universities and pharmaceutical companies on research projects (19), Kalodimou frequently publishes (49 & 11 books) her findings. She has 2 patents. She is a member of AABB involved in many committees as well as an AABB assessor.
As Chief Scientific Officer, Xiaokui Zhang, PhD is leading Aspen Neuroscience, Inc. current scientific programs, as well as future platform and pipeline investments for the autologous iPSC platform company.
Before joining Aspen, Dr. Zhang served as the Executive Vice President and Chief Scientific Officer at Celularity Inc., overseeing discovery, candidate development, preclinical, translational, process development and CMC activities to develop placenta-derived allogeneic, off-the-shelf cell therapy product candidates for immuno-oncology and functional regeneration applications, and serving as a member of the senior leadership team that took the company public in 2021. Dr. Zhang has also held various positions of increasing scope and responsibility at Celgene Cellular Therapeutics, and prior to Celgene, Dr. Zhang led a gene discovery team at Helicon Therapeutics and conducted target identification studies in cognitive disorders. Dr. Zhang’s research in functional characterizations of JAK-STAT signaling pathways and placental progenitor cell differentiation has resulted in numerous patents and publications in highly ranked journals including Science. She has also served as a mentor to early-stage professionals in the International Society for Cell & Gene Therapy (ISCT) and is the honoree of New Jersey Liberty Science Center Women in Science, Technology, Engineering and Mathematics (STEM) Award. Dr. Zhang received her undergraduate degree in Physiology from Nanjing University, Jiangsu, China and her doctorate in Molecular Cell Biology from the Rockefeller University, New York, New York, with further post-doctoral training in the Functional Genomics at Novartis Pharmaceuticals.
4550 Montgomery Avenue
Suite 700, North Tower
Bethesda, MD 20814
301.907.6977
